Literature DB >> 16902719

Socio-demographic profile and help-seeking behaviour of buprenorphine abusers in Singapore.

Munidasa Winslow1, Wei-Ling Ng, Subramaniam Mythily, Guo Song, Huak-Chan Yiong.   

Abstract

INTRODUCTION: The US Food and Drug Administration (FDA) approved buprenorphine or Subutex for the treatment of opiate dependence in October 2002. Buprenorphine is a partial agonist of the mu-opioid receptor; although initial animal research suggested a low abuse potential for buprenorphine, it was subsequently shown to have an abuse potential similar to that of morphine or hydromorphone. The objectives of this study were to establish the sociodemographic profile and help-seeking behaviour of buprenorphine abusers attending the deaddiction treatment clinics of the Community Addictions Management Programme.
MATERIALS AND METHODS: One hundred and twenty subjects, all buprenorphine abusers fulfilling the diagnostic criteria for opiate dependence, who consented to the study, completed an interviewer-administered questionnaire.
RESULTS: The mean age of those participating in the study was 39.2 [standard deviation (SD) 8.0] years. The majority of the participants were male (90%), 52.5% were currently employed and 98% had at least primary education. A family history of drug abuse was reported by 27% of the subjects. Illicit drug abuse occurred at an early age with mean age of onset of illicit drug abuse being 16.9 (SD 4.8) years with gateway drugs like marijuana and glue.
CONCLUSIONS: It is vital for our medical profession to be aware of the trend in the local population to move from the abuse of illicit substances, to the abuse of prescriptive medications. It makes it necessary to increase the understanding of addictions both amongst our practising medical fraternity, and amongst those training to enter the profession. At the hospital level, it necessitates a higher level of vigilance among our emergency room physicians and those treating infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16902719

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  5 in total

1.  Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.

Authors:  R Douglas Bruce; Sumathi Govindasamy; Laurie Sylla; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

2.  Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.

Authors:  David Otiashvili; Gvantsa Piralishvili; Zura Sikharulidze; George Kamkamidze; Sabrina Poole; George E Woody
Journal:  Drug Alcohol Depend       Date:  2013-07-31       Impact factor: 4.492

Review 3.  Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.

Authors:  Nikki Bozinoff; Vitor Tardelli; Dafna Sara Rubin-Kahana; Bernard Le Foll
Journal:  Harm Reduct J       Date:  2022-10-13

4.  Profile of substance use among patients attending De-addiction centres in a coastal city of southern India.

Authors:  Nithin Kumar; Tanuj Kanchan; Bhaskaran Unnikrishnan; Rekha Thapar; Prasanna Mithra; Vaman Kulkarni; Mohan Kumar Papanna; Ramesh Holla; Saran Sarathy
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

5.  A novel approach in the detoxification of intravenous buprenorphine dependence.

Authors:  Sukanto Sarkar; Eswaran Subramaniam; Janet Konthoujam
Journal:  Indian J Psychiatry       Date:  2016 Apr-Jun       Impact factor: 1.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.